OICR offers a number of funding opportunities for Ontario researchers throughout the year to help enable world-class cancer research across the province.
WOO Network Call for Concepts
The Ontario Institute for Cancer Research (OICR) Window-of-Opportunity (WOO) Network is inviting concept submissions for WOO trials, which exploit the ‘window’ of time after cancer diagnosis, typically prior to initiation of cancer therapy (usually surgery with curative intent). In presurgical WOO trials, patients with treatment naïve or early-stage disease are treated for a brief ‘window’ period with a novel therapy followed by surgical resection.
Funding support is provided to prioritized trial concepts that meet funding criteria. Investigators will present their concepts during the WOO Network Meeting on Thursday, February 9, 2023. Once prioritized, further trial development is engaged, facilitated and iterative.
OICR Innovation to Implementation
To accelerate translational cancer research so that precise, impactful and cost-effective treatments can benefit cancer patients, OICR has implemented a new Clinical Translation Pathway (CTP) to support preclinical, clinical, and convergent research. The CTP consists of four separate funding streams and is currently inviting applications for the Innovation to Implementation (I2I) funding opportunity which is focused on overcoming barriers to the mobilization, or uptake, of knowledge required to facilitate adoption of research into policy or healthcare. OICR is committed to providing research funding to help support a sustainable health system that enables fair and equitable access to cancer interventions.
Cancer Therapeutics Innovation Pipeline – Request for applications
The Cancer Therapeutics Innovation Pipeline (CTIP) Program was established to capitalize on Ontario’s expertise in cancer biology and drug discovery. Its aim is to create a pipeline of validated cancer targets and first-in-class or best-in-class, novel, selective lead molecules (small molecules or biologics) that will attract partnerships and/or investment for further preclinical and clinical development. To generate a sustainable pipeline, CTIP will support projects that aim to provide increasing evidence of target validation and disease association using data from knowledge bases, functional assays, and drug screening in relevant in vitro and in vivo models of the cancer type of interest.
Subscribe for New Opportunities
Only active opportunities are listed here. To be notified of new opportunities, please subscribe to our mailing list.